## In the Claims

## Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

- 1. (Original) An aerosol formulation comprising a biodegradable microsphere of average diameter of from 0.5 to 5µm comprising a non-living reagent that produces a protective immune response in a mammal to whom it is administered.
- 2. (Currently Amended) A<u>The</u> formulation according toof claim 1 wherein the said non-living reagent is antigenic polypeptide or a nucleic acid sequences which may encode such a polypeptide.
- 3. (Currently Amended) A<u>The</u> formulation according toof claim 2 wherein the said non-living reagent is a sub-unit vaccine.
- 4. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaims of claim 1 wherein the said non-living reagent is diptheria toxoid, tetanus toxoid, Botulinum toxin FHc, Bacillus anthracis protective antigen (PA) or a polypeptide which is capable of generating a protective immune response against Yersinia pestis.
- 5. (Currently Amended) AThe formulation according toof claim 4 wherein the non-living reagent is the V antigen of Y. pestis or an immunologically active fragment thereof or a variant of these, or the F1 antigen of Y. pestis or an immunologically active fragment thereof or a variant of these, or a combination of these.
- 6. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaims of claim 1 wherein the microspheres have an average diameter of less than 3μm.

U.S. National Phase of PCT/GB2004/000104

Filed: 15 July 2005

PRELIMINARY AMENDMENT

7. (Currently Amended) A<u>The</u> formulation according toof claim 6 wherein the microcapsules have an average diameter of between 1 and 1.5µm.

- 8. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaimsof claim 1 wherein the microspheres comprise a biodegradable polyester.
- 9. (Currently Amended) A<u>The</u> formulation according toof claim 8 wherein the polyester comprises Poly-lactide (PL).
- 10. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaimsof claim 1 wherein the microcapsules are lyophilised.
- 11. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaimsof claim 1 wherein the non-living reagent is encapsulated within the microspheres.
- 12. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaimsof claim 1 which further comprises the non-living reagent in free form.
- 13. (Currently Amended) A<u>The</u> formulation according toof claim 12 wherein the ratio of the amounts of the free reagent to the reagent associated with the microspheres is in the range of from 1:20 to 2:1.
- 14. (Currently Amended) A<u>The</u> formulation according to any one of the preceding elaimsof claim 1 in unit dosage form.
- 15. (Currently Amended) A nebulizer or inhaler comprising a formulation according to any one of the preceding claims of claim 1.
  - 16. (Cancelled)
- 17. (Currently Amended) A method of producing a protective immune response in a mammal in need thereof, said method comprising administering to the lung of said

U.S. National Phase of PCT/GB2004/000104

Filed: 15 July 2005

PRELIMINARY AMENDMENT

mammal, a protective amount of an aerosol formulation according to any one of claims 1 to 140f claim 1.